F2G Ltd., a UK-based antifungal drug discovery and development company, has appointed Ralf Schmid chief financial officer. Schmid carries 20 years’ experience to F2G and joins the company from Nabriva Therapeutics AG, where he was chief financial officer and chief operating officer. He also held senior positions in finance and administration at various multinational companies including Sandoz.
-
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Recent moves in the industry include C-suite changes at Abvance Therapeutics, plus Galapagos gets new chief financial officer from Horizon Therapeutics.
Recent moves in the industry include C-suite changes at Atalanta Therapeutics and Climb Bio, plus seven companies get new CMOs.
Recent moves in the industry include changes at the top at 32 Biosciences, plus new CEOs at Idorsia, Courage Therapeutics and Oncolytics Biotech.
Recent moves in the industry include changes at the top at iOnctura and Orca Bio, plus Sutro Biopharma, Tenpoint Therapeutics and Helix BioPharma get new CFOs.
The highlights of recent comments and insights from industry executives on the key issues covered in Scrip.
Fresh from having sold Anthos to Novartis, the new CEO is expected to update the oncology and dermatology-focused firm's strategy.
Recent moves in the industry include C-suite changes at Atalanta Therapeutics and Climb Bio, plus seven companies get new CMOs.
